Abstract
The failed outcome of autologous bone marrow transplantation for breast cancer opens the field for investigations. This is particularly important because the bone marrow could be a major source of cancer cells during tertiary metastasis. This review discusses subsets of breast cancer cells, including those that enter the bone marrow at an early period of disease development, perhaps prior to clinical detection. This population of cells evades chemotherapeutic damage even at high doses. An understanding of this population might be crucial for the success of bone marrow transplants for metastatic breast cancer and for the eradication of cancer cells in bone marrow. In vivo and in vitro studies have demonstrated gap junctional intercellular communication (GJIC) between bone marrow stroma and breast cancer cells. This review discusses GJIC in cancer metastasis, facilitating roles of mesenchymal stem cells (MSCs). In addition, the review addresses potential roles for miRNAs, including those already linked to cancer biology. The literature on MSCs is growing and their links to metastasis are beginning to be significant leads for the development of new drug targets for breast cancer. In summary, this review discusses interactions among GJIC, miRNAs and MSCs as future consideration for the development of cancer therapies.
Keywords: Breast cancer, bone marrow, gap junction, mesenchymal stem cells, microrna, stromal cells, metastasis, cytokines
Current Cancer Therapy Reviews
Title: microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Volume: 7 Issue: 3
Author(s): Larissa A. Gregory, Rachel A. Ricart, Shyam A. Patel, Philip K. Lim and Pranela Rameshwar
Affiliation:
Keywords: Breast cancer, bone marrow, gap junction, mesenchymal stem cells, microrna, stromal cells, metastasis, cytokines
Abstract: The failed outcome of autologous bone marrow transplantation for breast cancer opens the field for investigations. This is particularly important because the bone marrow could be a major source of cancer cells during tertiary metastasis. This review discusses subsets of breast cancer cells, including those that enter the bone marrow at an early period of disease development, perhaps prior to clinical detection. This population of cells evades chemotherapeutic damage even at high doses. An understanding of this population might be crucial for the success of bone marrow transplants for metastatic breast cancer and for the eradication of cancer cells in bone marrow. In vivo and in vitro studies have demonstrated gap junctional intercellular communication (GJIC) between bone marrow stroma and breast cancer cells. This review discusses GJIC in cancer metastasis, facilitating roles of mesenchymal stem cells (MSCs). In addition, the review addresses potential roles for miRNAs, including those already linked to cancer biology. The literature on MSCs is growing and their links to metastasis are beginning to be significant leads for the development of new drug targets for breast cancer. In summary, this review discusses interactions among GJIC, miRNAs and MSCs as future consideration for the development of cancer therapies.
Export Options
About this article
Cite this article as:
A. Gregory Larissa, A. Ricart Rachel, A. Patel Shyam, K. Lim Philip and Rameshwar Pranela, microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis, Current Cancer Therapy Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339411796234915
DOI https://dx.doi.org/10.2174/157339411796234915 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Profilin 1 Potentiates Apoptosis Induced by Staurosporine in Cancer Cells
Current Molecular Medicine Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Meet the Editorial Board
Current Medicinal Chemistry Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Current Drug Safety Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets The Epithelial-Mesenchymal Transition and the Estrogen-Signaling in Ovarian Cancer
Current Drug Targets Calreticulin is Differentially Expressed in Invasive Ductal Carcinoma: A Comparative Study
Current Proteomics Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets A Pan-cancer Analysis Reveals the Tissue Specificity and Prognostic Impact of Angiogenesis-associated Genes in Human Cancers
Current Bioinformatics The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Stilbenes and Xanthones from Medicinal Plants as Potential Antitumor Agents
Current Bioactive Compounds PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery Chip-Based High Throughput Screening of Herbal Medicines
Combinatorial Chemistry & High Throughput Screening WITHDRAWN: In silico and Experimental Analysis of miR-125b-5 and miR-485-5p Expression in Serum of Patients with Breast Cancer
MicroRNA Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets